Extended Data Table 1.

Remission state and time between last infusion of anti-CD20 antibody and COVID-19 vaccination in the Lymphoma (LY) subgroup Rx<12

Pseudonymized participant ID, disease, remission state, time from last anti-CD20 mAb infusion relative to the time-point of 1st, 2nd and 3rd vaccination, respectively, in days. Number of B cells per µl at visits #1-4 of the individual patient of this subgroup of 14 patients. “Remission state” is defined as the status of remission at the time of the first vaccination. Visits #1-4 are the time-points of blood sample collection as depicted in the time chart of the study in Fig. 1a. Visit #1: Pre-vaccination samples were collected shortly before vaccination #1. Visit #2: 2-8 weeks (median 35 days) after vaccination #2. Visit #3: 4-5 months (median 149 days) after vaccination #2. Visit #4: 2-8 weeks (median 40 days) after vaccination #3. Abbreviations: Rx<12: LY subgroup treated with anti-CD20 mAb less than 12 months before 1^st vaccination; *:median days; **:IQR of median days; P.ID: pseudonymized participant ID; LY: lymphoma; FL: follicular lymphoma; MCL: Mantle cell lymphoma; MZL: marginal zone lymphoma; CLL: chronic lymphocytic leukemia; MALT: mucosa-associated lymphoid tissue lymphoma; DLBCL: diffuse large B cell lymphoma; (Rx < 12): treated with rituximab <12 months before the 1^st vaccination.